Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-10-19
pubmed:abstractText
The pharmacokinetics of medetomidine administered as a single dose (80 micrograms/kg) were studied in rat, dog and cat with the tritium labelled drug. The results showed a rapid distribution, after an s.c. dose, of medetomidine radioactivity into rat tissues including the brains. In plasma/serum a distribution phase with a half-life of only a few minutes was observed. Peak concentration after i.m. administration (dog & cat) was seen within 0.5 h in complete accordance with the rapid onset of clinical effects. The apparent volumes of distribution ranged from 2.8 (dog, i.v.) to 3.5 l/kg (cat, i.m.) and clearances from 27.5 (dog, i.m.) to 33.4 ml/min kg (dog, i.v.). Elimination of medetomidine from plasma/serum occurred with half-lives ranging from 0.97 to 1.60 h. Differences between dosing routes were small. Elimination of radioactivity from rat brain tissue followed approximately the same time course as elimination from plasma suggesting that termination of clinical effects is controlled by removal of drug from CNS. Excretion of radioactivity was from 28.6 to 74.7% of the dose in three days. In each species most of the activity was excreted in urine. Fecal excretion was significant only in the rat. No measurable levels of the parent drug were found in excreta. Instead a hydroxylated product(s) and (their) conjugates (except in the cat) were present in urine. Other metabolites were not identified. It was concluded that elimination occurs mainly by biotransformation in the liver.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0065-1699
pubmed:author
pubmed:issnType
Print
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
49-54
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Pharmacokinetics of medetomidine.
pubmed:publicationType
Journal Article